With the advent of the aging era, the prevention and treatment of osteoporosis has become an important public health problem. In recent years, it has been found that there is a correlation between sympathetic nerve and bone metabolism, i.e., increased sympathetic tone leading to decreased bone anabolism and increased catabolism leading to loss of bone mass and destruction of bone structure. It is worth noting that different types and doses of sympathetic blockers may have different effects on bone metabolism. There are also differences between animal experiments and human experiments. In rodents, both selective β2 blockers and non-selective beta blockers play a role in bone protection. However, in humans, studies have shown that the preference for selective β1 blockers is more conducive to improving bone quality. The results of the dose study show that low-dose beta blockers are more beneficial in inhibiting bone resorption, reducing local inflammatory response, and promoting bone formation. However, high-dose beta blockers may have no effect on bone metabolism, and may even inhibit osteoblast activity, leading to increased bone loss. It can be seen that the difference in the dose of beta blocker may have an important impact on bone metabolism. In addition, new modes of administration such as transcutaneous iontophoresis of propranolol liposomes have emerged. At present, the clinical study of the influence of sympathetic nerve in bone metabolism is still in initial stage. This may provide a new idea for the prevention and treatment of osteoporosis. |